The Impact of PSMA PET on Prostate Cancer Treatment
David Morris, MD, FACS, discusses how PSMA PET imaging may impact targeted therapies for prostate cancer in the future.
ADT Intensification With Docetaxel is the Standard mCSPC Treatment Strategy
According to Alicia Morgans, MD, MPH, there is a consistent differentiation and benefit when AR-targeted agent is added to the androgen deprivation therapy plus docetaxel backbone.
Promising Targets for Bladder Cancer
Joshua J. Meeks, MD, discusses investigational targets in the bladder cancer space.
The Latest Treatment Advances in Prostate Cancer
In an interview with Targeted Oncology, Ashley Ross, MD, PhD, discussed his recent advanced in prostate cancer, research around prostate cancer genomics, PET for staging and for identification of local disease, and more.
2 Clarke Drive Cranbury, NJ 08512